Nothing Special   »   [go: up one dir, main page]

CN109963591A - B7h3抗体-药物偶联物及其医药用途 - Google Patents

B7h3抗体-药物偶联物及其医药用途 Download PDF

Info

Publication number
CN109963591A
CN109963591A CN201880004425.6A CN201880004425A CN109963591A CN 109963591 A CN109963591 A CN 109963591A CN 201880004425 A CN201880004425 A CN 201880004425A CN 109963591 A CN109963591 A CN 109963591A
Authority
CN
China
Prior art keywords
antibody
seq
sequence
chain variable
drug conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880004425.6A
Other languages
English (en)
Other versions
CN109963591B (zh
Inventor
顾津明
叶鑫
杨柳青
梁金栋
蒋贵阳
陶维康
张连山
应华
张玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changzhou Hengbang Pharmaceutical Co ltd
Hansen Shanghai Health Technology Co ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN109963591A publication Critical patent/CN109963591A/zh
Application granted granted Critical
Publication of CN109963591B publication Critical patent/CN109963591B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种B7H3抗体‑药物偶联物及其医药用途。具体而言，B7H3抗体‑细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物，以及包含前述偶联物或其药学上可接受的盐或溶剂化合物的药物组合物，以及其制备用于治疗B7H3介导的疾病或病症的药物中的用途；尤其在制备抗癌药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN201880004425.6A 2017-08-04 2018-08-03 B7h3抗体-药物偶联物及其医药用途 Active CN109963591B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710660432 2017-08-04
CN2017106604329 2017-08-04
PCT/CN2018/098480 WO2019024911A1 (zh) 2017-08-04 2018-08-03 B7h3抗体-药物偶联物及其医药用途

Publications (2)

Publication Number Publication Date
CN109963591A true CN109963591A (zh) 2019-07-02
CN109963591B CN109963591B (zh) 2023-04-04

Family

ID=65232283

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880004425.6A Active CN109963591B (zh) 2017-08-04 2018-08-03 B7h3抗体-药物偶联物及其医药用途

Country Status (3)

Country Link
CN (1) CN109963591B (zh)
TW (1) TW201909926A (zh)
WO (1) WO2019024911A1 (zh)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843927A (zh) * 2017-03-06 2019-06-04 江苏恒瑞医药股份有限公司 抗b7-h3抗体、其抗原结合片段及其医药用途
CN112543771A (zh) * 2018-09-30 2021-03-23 江苏恒瑞医药股份有限公司 抗b7h3抗体-依喜替康类似物偶联物及其医药用途
CN113933373A (zh) * 2021-12-16 2022-01-14 成都健数科技有限公司 一种利用质谱数据确定有机物结构的方法和系统
WO2022105879A1 (en) * 2020-11-20 2022-05-27 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Anti-cd276 antibody, antibody-drug conjugate, and use thereof
CN115103691A (zh) * 2020-03-25 2022-09-23 江苏恒瑞医药股份有限公司 一种含抗体药物偶联物的药物组合物及其用途
CN115279781A (zh) * 2020-03-26 2022-11-01 上海翰森生物医药科技有限公司 抗体药物偶联物及其医药用途
CN117025547A (zh) * 2023-10-08 2023-11-10 迈杰转化医学研究(苏州)有限公司 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用
WO2024114525A1 (zh) * 2022-11-29 2024-06-06 四川科伦博泰生物医药股份有限公司 B7-h3结合蛋白及其用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021190480A1 (zh) * 2020-03-24 2021-09-30 上海翰森生物医药科技有限公司 抗体-药物偶联物及其医药用途
WO2021190586A1 (zh) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 B7h3抗体-依喜替康类似物偶联物及其医药用途
MX2023011310A (es) 2021-03-26 2023-10-05 Innate Pharma Anclajes de citocina para proteinas de celulas nk de union a nkp46.
WO2022258662A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2023236949A1 (zh) * 2022-06-07 2023-12-14 映恩生物制药（苏州）有限公司 抗b7h3抗体-药物偶联物及其用途
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687945A (zh) * 2011-04-25 2014-03-26 第一三共株式会社 抗-b7-h3抗体
CN104755494A (zh) * 2012-10-11 2015-07-01 第一三共株式会社 抗体-药物偶联物
CA2990408A1 (en) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies
TW201718020A (zh) * 2015-06-23 2017-06-01 拜耳製藥公司 Ksp抑制劑與抗b7h3抗體之抗體藥物結合物(adc)
US20170355769A1 (en) * 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
CN109937212A (zh) * 2017-03-31 2019-06-25 江苏恒瑞医药股份有限公司 B7-h3抗体、其抗原结合片段及其医药用途
CN110090306A (zh) * 2018-01-31 2019-08-06 江苏恒瑞医药股份有限公司 双醛连接臂的配体-药物偶联物、其制备方法及其应用
CN110305213A (zh) * 2018-11-09 2019-10-08 上海复旦张江生物医药股份有限公司 一种抗b7-h3抗体及其制备方法、其偶联物和应用
CN113121639A (zh) * 2019-12-30 2021-07-16 江苏恒瑞医药股份有限公司 澳瑞他汀类似物及其偶联物、其制备方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523478A (ja) * 2007-03-22 2010-07-15 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ モノクローナル抗体８ｈ９の使用
CA2959356C (en) * 2014-08-27 2024-02-20 Memorial Sloan Kettering Cancer Center Novel antibodies that bind to b7h3
BR112017027690A2 (pt) * 2015-06-29 2018-10-09 Daiichi Sankyo Co Ltd “método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687945A (zh) * 2011-04-25 2014-03-26 第一三共株式会社 抗-b7-h3抗体
CN104755494A (zh) * 2012-10-11 2015-07-01 第一三共株式会社 抗体-药物偶联物
CA2990408A1 (en) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies
TW201718020A (zh) * 2015-06-23 2017-06-01 拜耳製藥公司 Ksp抑制劑與抗b7h3抗體之抗體藥物結合物(adc)
US20170355769A1 (en) * 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
CN109937212A (zh) * 2017-03-31 2019-06-25 江苏恒瑞医药股份有限公司 B7-h3抗体、其抗原结合片段及其医药用途
CN110090306A (zh) * 2018-01-31 2019-08-06 江苏恒瑞医药股份有限公司 双醛连接臂的配体-药物偶联物、其制备方法及其应用
CN110305213A (zh) * 2018-11-09 2019-10-08 上海复旦张江生物医药股份有限公司 一种抗b7-h3抗体及其制备方法、其偶联物和应用
CN113121639A (zh) * 2019-12-30 2021-07-16 江苏恒瑞医药股份有限公司 澳瑞他汀类似物及其偶联物、其制备方法及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NATHAN M. KENDSERSKY等: "The B7-H3-targeting antibody-drug conjugate m276-SL-PBD is", 《CLIN CANCER RES》 *
STEVEN SEAMAN等: "Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3 Positive Tumor Cells and Tumor Vasculature", 《CANCER CELL》 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843927A (zh) * 2017-03-06 2019-06-04 江苏恒瑞医药股份有限公司 抗b7-h3抗体、其抗原结合片段及其医药用途
CN109843927B (zh) * 2017-03-06 2022-06-21 江苏恒瑞医药股份有限公司 抗b7-h3抗体、其抗原结合片段及其医药用途
CN112543771A (zh) * 2018-09-30 2021-03-23 江苏恒瑞医药股份有限公司 抗b7h3抗体-依喜替康类似物偶联物及其医药用途
CN112543771B (zh) * 2018-09-30 2023-04-11 江苏豪森药业集团有限公司 抗b7h3抗体-依喜替康类似物偶联物及其医药用途
CN115103691A (zh) * 2020-03-25 2022-09-23 江苏恒瑞医药股份有限公司 一种含抗体药物偶联物的药物组合物及其用途
CN115279781A (zh) * 2020-03-26 2022-11-01 上海翰森生物医药科技有限公司 抗体药物偶联物及其医药用途
WO2022105879A1 (en) * 2020-11-20 2022-05-27 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Anti-cd276 antibody, antibody-drug conjugate, and use thereof
CN113933373A (zh) * 2021-12-16 2022-01-14 成都健数科技有限公司 一种利用质谱数据确定有机物结构的方法和系统
CN113933373B (zh) * 2021-12-16 2022-02-22 成都健数科技有限公司 一种利用质谱数据确定有机物结构的方法和系统
WO2024114525A1 (zh) * 2022-11-29 2024-06-06 四川科伦博泰生物医药股份有限公司 B7-h3结合蛋白及其用途
CN117025547A (zh) * 2023-10-08 2023-11-10 迈杰转化医学研究(苏州)有限公司 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用
CN117025547B (zh) * 2023-10-08 2023-12-12 迈杰转化医学研究(苏州)有限公司 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用

Also Published As

Publication number Publication date
TW201909926A (zh) 2019-03-16
CN109963591B (zh) 2023-04-04
WO2019024911A1 (zh) 2019-02-07

Similar Documents

Publication Publication Date Title
CN109963591A (zh) B7h3抗体-药物偶联物及其医药用途
JP7317272B2 (ja) Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。
JP7003036B2 (ja) グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法
TWI848090B (zh) 密蛋白抗體及其應用
AU2008323206B2 (en) AXL antibodies
CN103201290B (zh) S100a4抗体及其治疗用途
CN109937212A (zh) B7-h3抗体、其抗原结合片段及其医药用途
CN108472349A (zh) Lag-3抗体、其抗原结合片段及其医药用途
CN108779180A (zh) 新型抗-pd-l1抗体
KR20170036142A (ko) 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법
CN107135654A (zh) 巨胞饮人类抗cd46抗体和靶向癌症疗法
CN106659790A (zh) 抗cdh6抗体药物缀合物
US20210269521A1 (en) Bispecific antibody and use thereof
CN106573979A (zh) 抗axl抗体
US20210363266A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
US20030198638A1 (en) Tumor specific monoclonal antibodies
CN113906053B (zh) 抗cea抗体及其应用
CN109912715A (zh) 一种EGFRvIII抗体及其偶联物、制备方法和应用
CN110382532A (zh) 抗g-csf抗体及其用途
TW202108623A (zh) 抗ｔｒｏｐ－２抗體、其抗原結合片段及其醫藥用途
CN110090306A (zh) 双醛连接臂的配体-药物偶联物、其制备方法及其应用
TW202134286A (zh) 抗ｇｐｃ３抗體、其抗原結合片段及其醫藥用途
TWI685504B (zh) 抗gitr抗體、其抗原結合片段及其醫藥用途
CN108690136A (zh) 一种人源化抗tpbg抗体及其制备方法、其偶联物和应用
CN113597432B (zh) 抗EpCAM抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20231130

Address after: Room 101, No. 1158 Haike Road, No. 287 Xiangke Road, Pudong New Area Free Trade Pilot Zone, Shanghai, October 2012

Patentee after: Hansen (Shanghai) Health Technology Co.,Ltd.

Patentee after: Changzhou Hengbang Pharmaceutical Co.,Ltd.

Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.